Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …

Cancer is a leading cause of death worldwide. In many cases, the treatment of the disease is
limited due to the metastasis of cells to distant locations of the body through the blood and …

The RAF family of kinases includes key activators of the pro-tumourigenic mitogen-activated
protein kinase pathway. Hyperactivation of RAF proteins, particularly BRAF and CRAF …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

The increasing cancer morbidity and mortality requires the development of high-efficiency
and low-toxicity anticancer approaches. In recent years, photodynamic therapy (PDT) has …

Simple Summary Cutaneous melanoma represents the most aggressive form of skin cancer
and its occurrence, development, and progression are based on the accumulation of several …

Melanoma is a highly aggressive cancer with the poorest prognosis, representing the
deadliest form of skin cancer. Activating mutations in BRAF are the most frequent genetic …

Cutaneous melanoma is a common cancer and cases have steadily increased since the mid
70s. For some patients, early diagnosis and surgical removal of melanomas is lifesaving …

Simple Summary Immunotherapies and molecularly targeted therapies have drastically
changed the therapeutic approach for unresectable advanced or metastatic melanoma. The …

Simple Summary Survival after diagnosis of metastatic uveal melanoma has not significantly
improved over decades, most patients die within a year from diagnosis. Uveal melanoma is …